Señales en vivo de IPCIF | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 jun 2024 @ 15:53):
Our systems believe the stock currently is overvalued by -25.14% compare to its pairs and should correct downwards.

Stats
Volumen de hoy	2 598
Volumen promedio	4 227
Capitalización de mercado	3.84M
EPS	$-0.0571 ( Q3 \| 2023-10-16 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.110 (Sector) 0 (Industry) 0
ATR14	$0 (0.00%)

ACUT 16.78%

AIMD -3.89%

AKABY 0.00%

AOBI 0.00%

ARNI 417.24%

BETRF 0.00%

BRAXF 7.14%

BVNRY -7.81%

CLVLY -2.39%

COEP 1.05%

CPMV 0.00%

CRXM 0.00%

CSLLY 0.20%

ERGO 0.00%

GSTC 0.00%

IPCIF 0.00%

LVCLY 0.00%

MLCT 2.63%

NPTX 0.00%

NUGX 0.00%

OBMP -37.10%

OCEL -0.27%

ODTC 0.00%

OTLC 6.45%

PFND 0.00%

PROT 0.00%

PVCT 1.11%

QSAM -99.95%

RGBP 10.45%

RGBPP 0.00%

RSPI 8.11%

SIGY 0.00%

SILO 1.01%

SKYE 10.33%

SNNAQ 0.00%

SPHRY 0.00%

UCBJY 0.39%

USRM 0.00%

VGLS 100.00%

VICP 59.29%

WXXWY -1.02%

Correlación (AI algo v.1.1b): Overvalued: -25.14% $0.0939 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Intellipharmaceutics Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Intellipharmaceutics Finanzas

Annual	2023
Ingresos:	$65 728.00
Beneficio Bruto:	$65 728.00 (100.00 %)
EPS:	$-0.0874

FY	2023
Ingresos:	$65 728.00
Beneficio Bruto:	$65 728.00 (100.00 %)
EPS:	$-0.0874

FY	2022
Ingresos:	$65 728.00
Beneficio Bruto:	$-190 726 (-290.17 %)
EPS:	$-0.0983

FY	2020
Ingresos:	$1.40M
Beneficio Bruto:	$1.40M (100.00 %)
EPS:	$-0.140

Financial Reports:

No articles found.

Intellipharmaceutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Intellipharmaceutics

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.